Raptor Pharmaceuticals
Engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of .
Launch date
Market cap
-
Enterprise valuation
€55—82m (Dealroom.co estimates Aug 2010.)
Novato California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $50.0m | Post IPO Debt | |
| N/A | $10.0m | Debt | |
$60.0m | Post IPO Debt | ||
* | N/A | $85.5m | Post IPO Equity |
$800m | Acquisition | ||
| Total Funding | €15.8m | ||